A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression
Esteban Martínez*, José A. Arranz, Daniel Podzamczer, Montserrat Loncá, José Sanz, Patricia Barragán, Esteban Ribera, Hernando Knobel, Victor Roca, Félix Gutiérrez, José L. Blanco, Josep Mallolas, Josep M. Llibre, Bonaventura Clotet, David Dalmau, Ferran Segura, José R. Arribas, Jaime Cosín, Pilar Barrufet, Esperanza Casas
*Corresponding author for this work
- Universitat de Barcelona (UB)
- Hospital Universitari Principe de Asturias
- Complutense University of Madrid (UCM)
- Hospital General Universitario de Elche
- Hospital Sant Jaume de Calella
- IrsiCaixa AIDS Research Institute
- Parc Taulí University Hospital
- Universidad Autónoma de Madrid (UAM)
- Hospital de Mataró
- Universitat Pompeu Fabra (UPF)
- Vall d'Hebron University Hospital (HUVH)
- Universitat Autònoma de Barcelona (UAB)
Research output: Contribution to journal › Article › Research › peer-review
78
Link opens in a new tab
Citations
(Scopus)